Blockade of Immune Checkpoints in Lymph Nodes Through Locoregional Delivery Augments Cancer Immunotherapy

Overview

Journal Sci Transl Med

Specialties General Medicine
Science

Date 2020 Oct 1

PMID 32998971

Citations 116

Authors

David M Francis

Margaret P Manspeaker

Alex Schudel

Lauren F Sestito

Meghan J OMelia

Haydn T Kissick

Brian P Pollack

Edmund K Waller

Susan N Thomas

Affiliations

Soon will be listed here.

Abstract

Systemic administration of immune checkpoint blockade (ICB) monoclonal antibodies (mAbs) can unleash antitumor functions of T cells but is associated with variable response rates and off-target toxicities. We hypothesized that antitumor efficacy of ICB is limited by the minimal accumulation of mAb within tissues where antitumor immunity is elicited and regulated, which include the tumor microenvironment (TME) and secondary lymphoid tissues. In contrast to systemic administration, intratumoral and intradermal routes of administration resulted in higher mAb accumulation within both the TME and its draining lymph nodes (LNs) or LNs alone, respectively. The use of either locoregional administration route resulted in pronounced T cell responses from the ICB therapy, which developed in the secondary lymphoid tissues and TME of treated mice. Targeted delivery of mAb to tumor-draining lymph nodes (TdLNs) alone was associated with enhanced antitumor immunity and improved therapeutic effects compared to conventional systemic ICB therapy, and these effects were sustained at reduced mAb doses and comparable to those achieved by intratumoral administration. These data suggest that locoregional routes of administration of ICB mAb can augment ICB therapy by improving immunomodulation within TdLNs.

Citing Articles

Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics.

Nelson B, Naing A, Fu S, Sheth R, Murthy R, Piha-Paul S Immunooncol Technol. 2025; 25:101040.

PMID: 39981134 PMC: 11841068. DOI: 10.1016/j.iotech.2024.101040.

In vivo gene editing of T-cells in lymph nodes for enhanced cancer immunotherapy.

Qu J, Wang Y, Xiong C, Wang M, He X, Jia W Nat Commun. 2024; 15(1):10218.

PMID: 39587061 PMC: 11589603. DOI: 10.1038/s41467-024-54292-0.

Versatile tissue-injectable hydrogels capable of the extended hydrolytic release of bioactive protein therapeutics.

Nealy E, Reed S, Adelmund S, Badeau B, Shadish J, Girard E Bioeng Transl Med. 2024; 9(5):e10668.

PMID: 39553428 PMC: 11561820. DOI: 10.1002/btm2.10668.

VSV drives CD8 T cell-mediated tumour regression through infection of both cancer and non-cancer cells.

Rajwani J, Vishnevskiy D, Turk M, Naumenko V, Gafuik C, Kim D Nat Commun. 2024; 15(1):9933.

PMID: 39548070 PMC: 11567966. DOI: 10.1038/s41467-024-54111-6.

Therapeutic Immunomodulation of Tumor-Lymphatic Crosstalk via Intratumoral Immunotherapy.

Lucas S, Thomas S Mol Pharm. 2024; 21(12):5929-5943.

PMID: 39478434 PMC: 11615947. DOI: 10.1021/acs.molpharmaceut.4c00692.

References

Gros A, Parkhurst M, Tran E, Pasetto A, Robbins P, Ilyas S . Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016; 22(4):433-8. PMC: 7446107. DOI: 10.1038/nm.4051. View

Yost K, Satpathy A, Wells D, Qi Y, Wang C, Kageyama R . Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019; 25(8):1251-1259. PMC: 6689255. DOI: 10.1038/s41591-019-0522-3. View

Bulliard Y, Jolicoeur R, Windman M, Rue S, Ettenberg S, Knee D . Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med. 2013; 210(9):1685-93. PMC: 3754864. DOI: 10.1084/jem.20130573. View

Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M . Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med. 2014; 6(238):238ra70. PMC: 4558099. DOI: 10.1126/scitranslmed.3008211. View

Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S . Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Immunity. 2016; 44(4):924-38. PMC: 4980762. DOI: 10.1016/j.immuni.2016.03.012. View

Kleinovink J, Marijt K, Schoonderwoerd M, van Hall T, Ossendorp F, Fransen M . PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy. Oncoimmunology. 2017; 6(4):e1294299. PMC: 5414865. DOI: 10.1080/2162402X.2017.1294299. View

Rohner N, Thomas S . Melanoma growth effects on molecular clearance from tumors and biodistribution into systemic tissues versus draining lymph nodes. J Control Release. 2016; 223:99-108. PMC: 4724472. DOI: 10.1016/j.jconrel.2015.12.027. View

Brummelman J, Mazza E, Alvisi G, Colombo F, Grilli A, Mikulak J . High-dimensional single cell analysis identifies stem-like cytotoxic CD8 T cells infiltrating human tumors. J Exp Med. 2018; 215(10):2520-2535. PMC: 6170179. DOI: 10.1084/jem.20180684. View

Kumpers C, Jokic M, Haase O, Offermann A, Vogel W, Gratz V . Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma. Front Med (Lausanne). 2019; 6:27. PMC: 6425878. DOI: 10.3389/fmed.2019.00027. View

10.

van Hooren L, Sandin L, Moskalev I, Ellmark P, Dimberg A, Black P . Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. Eur J Immunol. 2016; 47(2):385-393. DOI: 10.1002/eji.201646583. View

11.

Ghoneim H, Fan Y, Moustaki A, Abdelsamed H, Dash P, Dogra P . De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell. 2017; 170(1):142-157.e19. PMC: 5568784. DOI: 10.1016/j.cell.2017.06.007. View

12.

Sade-Feldman M, Yizhak K, Bjorgaard S, Ray J, de Boer C, Jenkins R . Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018; 175(4):998-1013.e20. PMC: 6641984. DOI: 10.1016/j.cell.2018.10.038. View

13.

Selby M, Engelhardt J, Quigley M, Henning K, Chen T, Srinivasan M . Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2014; 1(1):32-42. DOI: 10.1158/2326-6066.CIR-13-0013. View

14.

Miller B, Sen D, Al Abosy R, Bi K, Virkud Y, LaFleur M . Subsets of exhausted CD8 T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019; 20(3):326-336. PMC: 6673650. DOI: 10.1038/s41590-019-0312-6. View

15.

Kourtis I, Hirosue S, de Titta A, Kontos S, Stegmann T, Hubbell J . Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PLoS One. 2013; 8(4):e61646. PMC: 3633981. DOI: 10.1371/journal.pone.0061646. View

16.

Ingram J, Blomberg O, Sockolosky J, Ali L, Schmidt F, Pishesha N . Localized CD47 blockade enhances immunotherapy for murine melanoma. Proc Natl Acad Sci U S A. 2017; 114(38):10184-10189. PMC: 5617302. DOI: 10.1073/pnas.1710776114. View

17.

Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T . CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res. 2014; 20(9):2424-32. PMC: 4008652. DOI: 10.1158/1078-0432.CCR-13-2648. View

18.

Knorr D, Dahan R, Ravetch J . Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity. Proc Natl Acad Sci U S A. 2018; 115(43):11048-11053. PMC: 6205479. DOI: 10.1073/pnas.1810566115. View

19.

Roberts E, Broz M, Binnewies M, Headley M, Nelson A, Wolf D . Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. Cancer Cell. 2016; 30(2):324-336. PMC: 5374862. DOI: 10.1016/j.ccell.2016.06.003. View

20.

Schudel A, Francis D, Thomas S . Material design for lymph node drug delivery. Nat Rev Mater. 2020; 4(6):415-428. PMC: 7286627. DOI: 10.1038/s41578-019-0110-7. View